Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis

Objective To examine the association between aberrant IgG galactosylation and disease parameters in rheumatoid arthritis (RA). Methods Analysis of N‐glycan in serum samples from multiple cohorts was performed. The IgG N‐glycan content and the timing of N‐glycan aberrancy relative to disease onset we...

Full description

Saved in:
Bibliographic Details
Published inArthritis and rheumatism Vol. 62; no. 8; pp. 2239 - 2248
Main Authors Ercan, Altan, Cui, Jing, Chatterton, Dereck E. W., Deane, Kevin D., Hazen, Melissa M., Brintnell, William, O'Donnell, Colin I., Derber, Lezlie A., Weinblatt, Michael E., Shadick, Nancy A., Bell, David A., Cairns, Ewa, Solomon, Daniel H., Holers, V. Michael, Rudd, Pauline M., Lee, David M.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2010
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective To examine the association between aberrant IgG galactosylation and disease parameters in rheumatoid arthritis (RA). Methods Analysis of N‐glycan in serum samples from multiple cohorts was performed. The IgG N‐glycan content and the timing of N‐glycan aberrancy relative to disease onset were compared in healthy subjects and in patients with RA. Correlations between aberrant galactosylation and disease activity were assessed in the RA cohorts. The impact of disease activity, sex, age, anti–cyclic citrullinated peptide (anti‐CCP) antibody titer, disease duration, and C‐reactive protein level on aberrant galactosylation was determined using multivariate analysis. The N‐glycan content was also compared between epitope affinity–purified autoantibodies and the remaining IgG repertoire in RA patients. Results Our results confirm the aberrant galactosylation of IgG in RA patients as compared with healthy controls (mean ± SD 1.36 ± 0.43 versus 1.01 ± 0.23; P < 0.0001). We observed a significant correlation between levels of aberrant IgG galactosylation and disease activity (Spearman's ρ = 0.37, P < 0.0001). This correlation was higher in women (Spearman's ρ = 0.60, P < 0.0001) than in men (Spearman's ρ = 0.16, P = 0.10). Further, aberrant IgG galactosylation substantially predated the onset of arthritis and the diagnosis of RA (3.5 years) and resided selectively in the anticitrullinated antigen fraction. Conclusion Our findings identify aberrant IgG galactosylation as a dysregulated component of the humoral immune response in RA that begins prior to disease onset, associates with disease activity in a sex‐specific manner, and resides preferentially in autoantibodies.
Bibliography:Drs. Bell and Cairns are coinventors on a patent for the synthetic citrullinated peptide JED, which was used in this study, but for which no remuneration was received.
Dr. Solomon has received fees for epidemiologic consulting from the Consortium of Rheumatology Researchers of North America (CORRONA) (more than $10,000), as well as research grants from Abbott and Amgen.
The views expressed herein are those of the authors and do not reflect the official policy of the Department of the Army, the Department of Defense, or the United States Government.
Dr. Weinblatt has received consulting fees and/or honoraria from Biogen Idec and Crescendo Biosciences (less than $10,000 each).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0004-3591
1529-0131
DOI:10.1002/art.27533